NasdaqGM:CATB

Stock Analysis Report

Executive Summary

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States.

Snowflake

Fundamentals

Flawless balance sheet with high growth potential.

Risks

  • Catabasis Pharmaceuticals has significant price volatility in the past 3 months.
  • Catabasis Pharmaceuticals is covered by less than 3 analysts.

Share Price & News

How has Catabasis Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

8.2%

NasdaqGM:CATB

0.2%

US Biotechs

0.2%

US Market


1 Year Return

0.7%

NasdaqGM:CATB

-9.1%

US Biotechs

-0.7%

US Market

CATB outperformed the Biotechs industry which returned -7.3% over the past year.

CATB matched the United States of America Market (0.3%) over the past year.


Share holder returns

CATBIndustryMarket
7 Day8.2%0.2%0.2%
30 Day-7.6%0.9%-2.7%
90 Day-10.7%2.4%1.6%
1 Year0.7%0.7%-8.4%-9.1%1.6%-0.7%
3 Year-86.6%-86.6%8.3%4.6%40.0%30.9%
5 Yearn/a4.5%-0.3%53.8%36.8%

Price Volatility Vs. Market

How volatile is Catabasis Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Catabasis Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

1.76x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Catabasis Pharmaceuticals to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Catabasis Pharmaceuticals to establish if it is available at substantial discount.


Price Based on Earnings

Catabasis Pharmaceuticals is loss making, we can't compare its value to the US Biotechs industry average.

Catabasis Pharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Catabasis Pharmaceuticals, we can't assess if its growth is good value.


Price Based on Value of Assets

Catabasis Pharmaceuticals is good value based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is Catabasis Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

66.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Catabasis Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.

Catabasis Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.

Catabasis Pharmaceuticals's revenue growth is expected to exceed the United States of America market average.

Catabasis Pharmaceuticals's earnings growth is expected to exceed the United States of America market average.

Catabasis Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Catabasis Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Catabasis Pharmaceuticals performed over the past 5 years?

0.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Catabasis Pharmaceuticals does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare Catabasis Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Catabasis Pharmaceuticals's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Catabasis Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Catabasis Pharmaceuticals has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Catabasis Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Catabasis Pharmaceuticals's financial position?


Financial Position Analysis

Catabasis Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Catabasis Pharmaceuticals has no long term commitments.


Debt to Equity History and Analysis

Catabasis Pharmaceuticals's level of debt (-0.8%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (17.6% vs -0.8% today).


Balance Sheet

Low level of unsold assets.

Debt is not covered by short term assets, assets are -142.4x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Catabasis Pharmaceuticals has sufficient cash runway for 2 years based on current free cash flow.

Catabasis Pharmaceuticals has sufficient cash runway for 2.2 years if free cash flow continues to reduce at historical rates of -15.8% each year.


Next Steps

Dividend

What is Catabasis Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Catabasis Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Catabasis Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Catabasis Pharmaceuticals has not reported any payouts.

Unable to verify if Catabasis Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Catabasis Pharmaceuticals has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Catabasis Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Catabasis Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

3.8yrs

Average management tenure


CEO

Jill Milne (51yo)

11.2yrs

Tenure

US$1,136,169

Compensation

Ms. Jill C. Milne, PhD is the Co-founder of Catabasis Pharmaceuticals, Inc., has been its President and Chief Executive Officer since June 2008 and also served as Principal Financial Officer since April 8, ...


CEO Compensation Analysis

Jill's remuneration is higher than average for companies of similar size in United States of America.

Jill's compensation has increased whilst company is loss making.


Management Age and Tenure

3.8yrs

Average Tenure

56yo

Average Age

The tenure for the Catabasis Pharmaceuticals management team is about average.


Board Age and Tenure

3.4yrs

Average Tenure

65yo

Average Age

The tenure for the Catabasis Pharmaceuticals board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Deirdre Cunnane (54yo)

    Chief Legal Officer & Treasurer

    • Tenure: 3.8yrs
  • Jill Milne (51yo)

    Co-Founder

    • Tenure: 11.2yrs
    • Compensation: US$1.14m
  • Andy Nichols (58yo)

    Chief Scientific Officer

    • Tenure: 2.8yrs
    • Compensation: US$715.27k
  • Joanne Donovan (62yo)

    Chief Medical Officer & Senior VP of Clinical Development

    • Tenure: 8.1yrs
    • Compensation: US$827.09k
  • Noah Clauser

    VP of Finance & Controller

    • Tenure: 2.0yrs

Board Members

  • Burt Adelman (67yo)

    Independent Director

    • Tenure: 3.3yrs
    • Compensation: US$59.35k
  • Mike Kishbauch (70yo)

    Independent Director

    • Tenure: 3.3yrs
    • Compensation: US$66.85k
  • Ken Bate (69yo)

    Chairman of the Board

    • Tenure: 3.5yrs
    • Compensation: US$91.85k
  • Jill Milne (51yo)

    Co-Founder

    • Tenure: 11.2yrs
    • Compensation: US$1.14m
  • Gregg Lapointe (60yo)

    Director

    • Tenure: 0.6yrs
  • John Kastelein (65yo)

    Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Mike Jirousek (60yo)

    Member of Scientific Advisory Board

    • Tenure: 3.8yrs
    • Compensation: US$700.79k
  • Jay Horton

    Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Roger Ulrich

    Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Eric Brass

    Member of Scientific Advisory Board

    • Tenure: 0.0yrs

Company Information

Catabasis Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Catabasis Pharmaceuticals, Inc.
  • Ticker: CATB
  • Exchange: NasdaqGM
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$76.673m
  • Shares outstanding: 11.62m
  • Website: https://www.catabasis.com

Number of Employees


Location

  • Catabasis Pharmaceuticals, Inc.
  • Building 1400E
  • Suite B14202
  • Cambridge
  • Massachusetts
  • 2139
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CATBNasdaqGM (Nasdaq Global Market)YesCommon SharesUSUSDJun 2015
209ADB (Deutsche Boerse AG)YesCommon SharesDEEURJun 2015

Biography

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/21 00:24
End of Day Share Price2019/08/20 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.